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Over the past 10 years, the treatment of multiple myeloma (MM) dramatically changed due to the
introduction of a number of new agents and combination regimens both in the frontline and in the
relapsed/refractory setting. Currently, at least 11 classes of therapeutic agents, including steroids,
alkylators (melphalan and cyclophosphamide), proteasome inhibitors (PI: bortezomib, carfilzomib,
ixazomib), immunomodulatory agents (thalidomide, lenalidomide, pomalidomide), monoclonal
antibodies (mAbs: elotuzumab, daratumumab), HDAC-inhibitors (panobinostat), BCL2 inhibitors
(venetoclax), selective inhibitors of nuclear export (selinexor), drug-conjugated mAbs (belantamab
mafodotin), bispecific agents and CAR-T, are approved (or are going to be approved) alone or in
different combinations for the treatment of this disease, while few or no data are available to guide
the therapeutic strategy to adopt at diagnosis or relapse (1). The choice of the treatment at relapse
(2), in particular, poses particular challenges, and is currently dependent on patients (age,
comorbidities, fitness, renal impairment, frailty) and disease characteristics (aggressive vs
biochemical relapse, cytogenetics, presence of extra-medullary disease), previous treatments
(classes of agents, duration of response, progression while on therapy), regional drug access
(approval of combinations, reimbursement, costs) and, finally, patient’s choice. Unfortunately,
there is a lack of trials specifically designed to help in this choice, and often, pre-planned subgroup
analyses, do not include a sufficient number of patients to reach statistical evidence. Recently, since
lenalidomide is progressively becoming the preferred one-line option to treat MM patients (and
often, it is administered until progression), the choice of the treatment to be offered at relapse should
be carefully evaluated. Interestingly, it has been reported that the longest prior lenalidomide
treatment duration (>12 months) and IMiD-free interval (>18 months) could positively impact
patients’ outcome (3), making the choice of a lenalidomide-sparing regimen of particular interest in
this setting. On the bases of these premises, we performed a systematic review and a frequentist
network meta-analysis in R [by using the netmeta package (4)] comparing direct and indirectApril 2021 | Volume 11 | Article 6434901
Botta et al. Network Meta-Analysis of Lenalidomide-Sparing Regimensevidence on the efficacy of seven different lenalidomide-sparing
regimens (bortezomib-dexamethasone, VD; daratumumab-VD,
DVD; carfi lzomib-D, KD; daratumumab-KD, KdD;
pomalidomide-VD, PVD; isatuximab-KD, IKD; selinexor-VD,
SVD) in lenalidomide-exposed and lenalidomide-refractory
patients, to provide statistical evidence to support clinical
decision making (Supplementary Figure 1).EVIDENCE FROM CLINICAL TRIALS
Overall, we included 1,616 relapsed refractory MM patients
(RR/MM) previously exposed to lenalidomide (lena-exposed)
and 984 RR/MM patients reported to be lenalidomide
refractory (lena-refractory) included in six randomized phase
3 trials (5–10). Figure 1A (and Supplementary Figure 1)
reports the distribution of patients according to treatment
and the presence of direct comparisons. All the groups were
well balanced for presence of lena-refractory patients (about
70%, with the exception of the Castor trial which, within theFrontiers in Oncology | www.frontiersin.org 2lena-exposed population, only included about 50% of lena-
refractory patients), exposure to bortezomib (about 65%, with
the exception of the aCD38_KD group were about 90% of
patients have been previously exposed to bortezomib) (Table 1)
and patients treated in second line (about 45% in all trials, data
not shown). Hazard ratios for PFS were included in our study.
As reported in Figures 1B and C, all the treatments appear to
be significantly superior to VD in both the lenalidomide
exposed and refractory setting (with the exception of KD in
the refractory group). Interestingly, DVD resulted to be
significantly better than VD, KD, and PVD, slightly better
than SVD (without reaching the statistical significance) and
equal to both IKD and KdD in the lena-exposed population
(Supplementary Figure 2). The same results are observed
within the lena-refractory population, where DVD shows a
trend of superiority over PVD and a significant advantage over
both KD and VD. Looking at the P scores (the equivalent of the
SUCRA score in frequentist NMA (4)), the triplets including an
anti-CD38 mAb and a PI, always outperforms PVD and the
doublets VD and KD (Figure 1D). These results are in line withA B
C D
FIGURE 1 | (A) Network plot showing all the direct comparisons and the number of patients included in each node (i.e. the total number of patients receiving the
treatment indicated in the node). (B, C) forest-plots indicating the efficacy of each regimen (in terms of hazards ratio (HR) and 95% confidence intervals) by using VD
as comparator arms. (D) Ranking charts of all the evaluated regimens based on the P-score and grouped according to previous exposition or resistance to
lenalidomide. VD, bortezomib-dexamethasone; DVD, daratumumab-VD; SVD, selinexor-VD; PVD, pomalidomide-VD; KD, carfilzomib-dexamethasone; KdD,
daratumumab-KD; IKD, isatuximab-KD.April 2021 | Volume 11 | Article 643490
Botta et al. Network Meta-Analysis of Lenalidomide-Sparing Regimensour previous work where we demonstrated in pairwise meta-
analysis the advantage of triplets over doublets in the RRMM
setting (1).DISCUSSION
Currently, no guidelines exist, which help decision making in the
lenalidomide exposed or refractory setting. The last European
guideline (11), indicates, due to the plethora of new agents
currently available for MM treatment, to perform a class-switch
whenever possible at the time of relapse, without indicating the best
regimen to choose. The absence of precise indications mainly
depends on the lack of direct comparisons between the available
regimens together with the lack of preplanned subgroup analysis
“numerically”designed to answer thesequestions.Toovercome this
limitation, we used the NMA approach, demonstrating that,
whenever possible, the combination of an anti-CD38 agent with a
PI should represent thefirst choice inorder to achieve thebest result
in termofPFS in both the lena-exposed and lena-refractory RRMM
population. However, while these results are of strong clinical
interest, some limitations due to the methodology should be
taken into account: for instance, the NMA is based on indirect
evidence (other than on direct evidence), which could intrinsically
introducebiases andondata retrieved frompublished studies rather
than from individual patients. Additionally, while patients’
characteristics are very similar between the studies included in the
NMA, small or unknown differences, such as the distribution of
patients according to treatment line, could impact the final results:
e.g., theCASTORtrial (10) includes,within the lena-exposedgroup,
about 50% of patients refractory to lenalidomide, which is a lower
than what reported in the other trials; however the advantage of
DVD was confirmed even in the lena-refractory subgroup,
rendering this difference acceptable. Furthermore, few or no data
are currently available on the activity of lenalidomide-based triplets
or quadruplets (thus excluded from this analysis) in lena-refractory
patients as well as on the efficacy of lenalidomide ramp-up in
patients progressing during 10 mg maintenance. Along the same
line, the efficacy of the new pomalidomide/mAbs combo regimens,
which look very promising, could not be evaluated with thisFrontiers in Oncology | www.frontiersin.org 3approach, mainly due to the fact that all the investigational
clinical trials have been performed in more advanced settings
(from the third line of therapy) by using (always) PD as control
arm (12–14). Translational investigations, which shed light on the
biologic interplay which take place within the bone marrow
microenvironment (15–19) are eagerly awaited and could help to
develop new therapeutic approaches in this setting. Finally, this
work should be considered a snapshot of current evidence, taking
into account that some of these drugs will probably move to the
frontline setting.
To the best of our knowledge, this is the first NMA designed to
compare the efficacyof lena-sparing regimens inRRMMpreviously
exposed or refractory to lenalidomide. Our findings suggest that
among the currently approved regimens, DVD (or KdD/IKDwhen
available) has the highest probability of being the best treatment in
both lenalidomide previously exposed or refractory setting, further
underscoring how mAbs represents a very important addition to
the therapeutic armamentarium available for the treatment ofMM
patients. However, taking into account that, even with these
regimens, the reported median PFS is about 9 months,
prospective randomized trials investigating new agents and
combinations are needed to identify better therapeutic options for
this high-risk MM population.AUTHOR CONTRIBUTIONS
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643490/full#supplementary-materialTABLE 1 | Main characteristics and previous treatments of the clinical trials included in the network meta-analysis.
Trials/Authors treatment total pts LEN previously exposed LEN refractory % BORT previously exposed %
Castor/Palumbo DVD 251 89 45 50,6 162 64,5
VD 247 120 60 50,0 164 66,4
Endeavor/Dimopoulos KD 464 177 113 63,8 250 53,9
VD 465 177 122 68,9 252 54,2
Optimismm/Richardson PVD 281 281 200 71,2 201 71,5
VD 278 278 191 68,7 203 73,0
Candor/Dimopoulos KdD 312 123 99 80,5 287 92,0
KD 154 74 55 74,3 134 87,0
Ikema/Moreau IKD 179 81 57 70,4 166 92,7
KD 123 62 42 67,7 105 85,4
Boston/Dimopoulos SVD 195 77 134 68,7
VD 207 77 145 70,0April 2021 | Volume 11 | Article 64VD, bortezomib-dexamethasone; DVD, daratumumab-VD; SVD, selinexor-VD; PVD, pomalidomide-VD; KD, carfilzomib-dexamethasone; KdD, daratumumab-KD; IKD, isatuximab-KD.3490
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